Journal of Cardiovascular Disease Research
IMPACT OF EARLY REMEDESIVIR THERAPY ON COVID 19 PROGRESSION IN COMMUNITY SETTINGS
Kalyani Deenadayalan, Prashant Mane, Nabeel Ahmed Gadi, Vishal V. Gore
JCDR. 2024: 233 -239
Abstract
Background: The COVID-19 pandemic, caused by SARS-CoV-2, continues to necessitate effective treatment strategies. Remdesivir, an antiviral agent, has shown promise in hospitalized patients, but its impact in community settings and when administered early in the disease course remains underexplored. Methods: This retrospective cohort study analyzed 120 patients diagnosed with COVID-19 in community settings, split equally into two groups: one receiving early Remdesivir therapy within 48 hours of diagnosis and the other not receiving Remdesivir. We assessed the impact of treatment on disease progression, time to clinical recovery, hospitalization rates, and safety profiles
» PDF